Compare KYMR & ONTO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | KYMR | ONTO |
|---|---|---|
| Founded | 2015 | 1940 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medicinal Chemicals and Botanical Products | Industrial Machinery/Components |
| Sector | Health Care | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.4B | 10.9B |
| IPO Year | 2020 | N/A |
| Metric | KYMR | ONTO |
|---|---|---|
| Price | $69.51 | $219.44 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 24 | 8 |
| Target Price | $105.35 | ★ $176.25 |
| AVG Volume (30 Days) | 743.7K | ★ 763.4K |
| Earning Date | 02-26-2026 | 02-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 3.55 |
| Revenue | $43,735,000.00 | ★ $1,002,336,000.00 |
| Revenue This Year | $18.70 | $3.72 |
| Revenue Next Year | N/A | $17.29 |
| P/E Ratio | ★ N/A | $62.03 |
| Revenue Growth | N/A | ★ 6.38 |
| 52 Week Low | $19.45 | $85.88 |
| 52 Week High | $103.00 | $228.42 |
| Indicator | KYMR | ONTO |
|---|---|---|
| Relative Strength Index (RSI) | 39.39 | 82.25 |
| Support Level | $71.46 | $176.00 |
| Resistance Level | $76.71 | $227.07 |
| Average True Range (ATR) | 3.72 | 7.55 |
| MACD | -1.19 | 4.17 |
| Stochastic Oscillator | 4.32 | 88.38 |
Kymera Therapeutics Inc is a clinical-stage biopharmaceutical company dedicated to reinventing the treatment of human disease through the development of, differentiated medicines that address health problems and that meaningfully improve patients' lives. It is committed to novel technologies to address targets that have known disease-causing biology, but which have not been drugged, or have been inadequately drugged, often based on limitations of existing technologies. Its approach is intended to discover and develop a new generation of medicines in a disease-agnostic manner. Its product pipelines are STAT6, TYK2, and IRAK4.
Onto Innovation Inc is engaged in the design, development, manufacture, and support of high-performance control metrology, defect inspection, lithography, and data analysis systems used by microelectronics device manufacturers. The Company and its subsidiaries currently operate in a single operating segment. The company mainly operates in the United States, Southeast Asia, China, Japan, and Europe, with Taiwan and South Korea the sources of total revenue.